Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study.


Journal

BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449

Informations de publication

Date de publication:
27 04 2019
Historique:
received: 11 07 2018
accepted: 05 04 2019
entrez: 29 4 2019
pubmed: 29 4 2019
medline: 31 1 2020
Statut: epublish

Résumé

Adverse drug events (ADEs) are a significant cause of emergency department (ED) visits, with a major impact on healthcare resource utilization. A multicentre observational study, aimed to describe frequency, seriousness and preventability of ADEs reported in four EDs, was performed in Sicily (Italy) over a 1-year period. Two trained monitors for each ED supported clinicians in identifying ADEs of patients admitted to EDs between June 1st, 2013 and May 31st, 2014 through a systematic interview of patients or their caregivers and with an additional record review. A research team analyzed each case of suspected ADE, to make a causality assessment applying the Naranjo algorithm and a preventability assessment using Schumock and Thornton criteria. Absolute and percentage frequencies with 95% confidence interval (CI) and medians with interquartile ranges (IQR) were estimated. Logistic regression models were used to evaluate independent predictors of serious and certainly preventable ADEs. Out of 16,963 ED visits, 575 (3.4%) were associated to ADEs, of which 15.1% resulted in hospitalization. ADEs were classified as probable in 45.9%, possible in 51.7% and definite in 2.4% of the cases. Moreover, ADEs were considered certainly preventable in 12.3%, probably preventable in 58.4%, and not preventable in 29.2% of the cases. Polytherapy influenced the risk to experience a serious, as well as a certainly preventable ADE. Whilst, older age resulted an independent predictor only of serious events. The most common implicated drug classes were antibiotics (34.4%) and anti-inflammatory drugs (22.6%). ADEs due to psycholeptics and antiepileptics resulted preventable in 62.7 and 54.5% of the cases, respectively. Allergic reactions (64%) were the most frequent cause of ADE-related ED visits, followed by neurological effects (10.2%) that resulted preventable in 1.9 and 37.3% of the cases, respectively. ADEs are a frequent cause of ED visits. The commonly used antibiotics and anti-inflammatory drugs should be carefully managed, as they are widely involved in mild to severe ADEs. Polytherapy is associated with the occurrence of serious, as well as certainly preventable ADEs, while older age only with serious events. A greater sensitivity to drug monitoring programs among health professionals is needed.

Sections du résumé

BACKGROUND
Adverse drug events (ADEs) are a significant cause of emergency department (ED) visits, with a major impact on healthcare resource utilization. A multicentre observational study, aimed to describe frequency, seriousness and preventability of ADEs reported in four EDs, was performed in Sicily (Italy) over a 1-year period.
METHODS
Two trained monitors for each ED supported clinicians in identifying ADEs of patients admitted to EDs between June 1st, 2013 and May 31st, 2014 through a systematic interview of patients or their caregivers and with an additional record review. A research team analyzed each case of suspected ADE, to make a causality assessment applying the Naranjo algorithm and a preventability assessment using Schumock and Thornton criteria. Absolute and percentage frequencies with 95% confidence interval (CI) and medians with interquartile ranges (IQR) were estimated. Logistic regression models were used to evaluate independent predictors of serious and certainly preventable ADEs.
RESULTS
Out of 16,963 ED visits, 575 (3.4%) were associated to ADEs, of which 15.1% resulted in hospitalization. ADEs were classified as probable in 45.9%, possible in 51.7% and definite in 2.4% of the cases. Moreover, ADEs were considered certainly preventable in 12.3%, probably preventable in 58.4%, and not preventable in 29.2% of the cases. Polytherapy influenced the risk to experience a serious, as well as a certainly preventable ADE. Whilst, older age resulted an independent predictor only of serious events. The most common implicated drug classes were antibiotics (34.4%) and anti-inflammatory drugs (22.6%). ADEs due to psycholeptics and antiepileptics resulted preventable in 62.7 and 54.5% of the cases, respectively. Allergic reactions (64%) were the most frequent cause of ADE-related ED visits, followed by neurological effects (10.2%) that resulted preventable in 1.9 and 37.3% of the cases, respectively.
CONCLUSION
ADEs are a frequent cause of ED visits. The commonly used antibiotics and anti-inflammatory drugs should be carefully managed, as they are widely involved in mild to severe ADEs. Polytherapy is associated with the occurrence of serious, as well as certainly preventable ADEs, while older age only with serious events. A greater sensitivity to drug monitoring programs among health professionals is needed.

Identifiants

pubmed: 31029178
doi: 10.1186/s40360-019-0297-7
pii: 10.1186/s40360-019-0297-7
pmc: PMC6486973
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Inflammatory Agents 0
Fibrinolytic Agents 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21

Références

Eur J Intern Med. 2014 Jan;25(1):49-55
pubmed: 24200546
Biomed Res Int. 2014;2014:268362
pubmed: 25506054
PLoS One. 2014 Jul 29;9(7):e102146
pubmed: 25072244
Drug Saf. 1999 Feb;20(2):109-17
pubmed: 10082069
Drugs Aging. 2012 Aug 1;29(8):669-79
pubmed: 22775477
Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1099-106
pubmed: 23963962
BMC Clin Pharmacol. 2007 Jul 28;7:8
pubmed: 17662147
Eur J Clin Pharmacol. 2008 Jun;64(6):619-25
pubmed: 18213473
CJEM. 2008 Sep;10(5):421-7
pubmed: 18826729
Epilepsy Res. 2009 Jul;85(1):107-13
pubmed: 19345564
Drug Saf. 2012 Sep 1;35(9):769-81
pubmed: 22823502
JAMA. 2016 Nov 22;316(20):2115-2125
pubmed: 27893129
Ann Emerg Med. 2005 Feb;45(2):197-206
pubmed: 15671977
Eur J Clin Pharmacol. 1999 Feb;54(12):959-63
pubmed: 10192758
Eur J Clin Pharmacol. 2005 Sep;61(8):615-20
pubmed: 16044339
Qual Saf Health Care. 2003 Aug;12(4):280-5
pubmed: 12897361
Drug Saf. 2017 Jul;40(7):597-606
pubmed: 28382494
Pharmacoeconomics. 2003;21(9):623-50
pubmed: 12807365
BMC Med Res Methodol. 2018 Dec 4;18(1):160
pubmed: 30514232
Clinicoecon Outcomes Res. 2014 Dec 03;6:505-14
pubmed: 25506231
CMAJ. 2008 Jun 3;178(12):1563-9
pubmed: 18519904
JAMA. 2006 Oct 18;296(15):1858-66
pubmed: 17047216
Emerg Med J. 2013 Jan;30(1):63-7
pubmed: 22366041
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Br J Clin Pharmacol. 1997 Feb;43(2):177-81
pubmed: 9131950
BMC Health Serv Res. 2013 Nov 12;13:473
pubmed: 24219303
Front Pharmacol. 2018 Apr 11;9:350
pubmed: 29695966
Eur J Clin Pharmacol. 1998 Aug;54(6):483-8
pubmed: 9776440
Pharmacoepidemiol Drug Saf. 2005 May;14(5):333-40
pubmed: 15682429
BMC Pharmacol Toxicol. 2018 Apr 16;19(1):16
pubmed: 29661234
Pharmacol Res. 2004 Dec;50(6):631-6
pubmed: 15501703
Ann Pharmacother. 1999 Dec;33(12):1252-7
pubmed: 10630823
BMC Pharmacol Toxicol. 2017 Dec 8;18(1):79
pubmed: 29216902
Br J Clin Pharmacol. 2010 Oct;70(4):514-22
pubmed: 20840443
PLoS One. 2012;7(3):e33236
pubmed: 22438900
Eur J Clin Pharmacol. 2003 Nov;59(8-9):651-7
pubmed: 13680039
PLoS One. 2009;4(2):e4439
pubmed: 19209224
Ann Pharmacother. 2002 Jan;36(1):30-9
pubmed: 11816254
Br J Clin Pharmacol. 2006 Nov;62(5):582-90
pubmed: 16822281
Circ Heart Fail. 2014 Jan;7(1):28-34
pubmed: 24300242
Gac Sanit. 2011 Nov-Dec;25(6):501-6
pubmed: 21835509
Diabetes Res Clin Pract. 2015 Apr;108(1):157-63
pubmed: 25686508
J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S47-50
pubmed: 24347982
Age Ageing. 2009 Jul;38(4):358-9
pubmed: 19420141
Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):279-81
pubmed: 23527735
CJEM. 2010 Sep;12(5):421-30
pubmed: 20880432
Parkinsonism Relat Disord. 2008;14(5):420-5
pubmed: 18316232
BMC Pharmacol Toxicol. 2017 Nov 15;18(1):71
pubmed: 29141696
Int J Clin Pharm. 2013 Jun;35(3):327-31
pubmed: 23549774
PLoS One. 2015 Apr 16;10(4):e0122899
pubmed: 25880729
Pharmacotherapy. 2002 Jul;22(7):915-23
pubmed: 12126224
J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):46-51
pubmed: 24565768
Eur J Clin Pharmacol. 2009 Jul;65(7):721-8
pubmed: 19294371
Pharm World Sci. 2008 Jan;30(1):44-50
pubmed: 17588130
PLoS One. 2014 Feb 18;9(2):e89072
pubmed: 24558471
Emerg Med J. 2014 Jan;31(1):24-9
pubmed: 23389832
Hosp Pharm. 1992 Jun;27(6):538
pubmed: 10118597
Br J Clin Pharmacol. 2015 Jun;79(6):1010-9
pubmed: 25556909

Auteurs

Ivan Lo Giudice (I)

Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.

Eleonora Mocciaro (E)

Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.

Claudia Giardina (C)

Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.

Maria Antonietta Barbieri (MA)

Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.

Giuseppe Cicala (G)

Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.

Maria Gioffrè-Florio (M)

Department of Emergency Medicine, University Hospital G. Martino, Via Consolare Valeria, 98125, Messina, Italy.

Giuseppe Carpinteri (G)

Department of Emergency Medicine, University Hospital V. Emanuele, Via S. Sofia, 95123, Catania, Italy.

Aulo Di Grande (A)

Department of Emergency Medicine, General Hospital S. Elia, Via Luigi Russo, 93100, Caltanissetta, Italy.

Edoardo Spina (E)

Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy.
Sicilian Regional Pharmacovigilance Center, Clinical Pharmacology Unit, University Hospital G. Martino, Via Consolare Valeria, 98125, Messina, Italy.

Vincenzo Arcoraci (V)

Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, Italy. vincenzo.arcoraci@unime.it.

Paola Maria Cutroneo (PM)

Sicilian Regional Pharmacovigilance Center, Clinical Pharmacology Unit, University Hospital G. Martino, Via Consolare Valeria, 98125, Messina, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH